Short Term Outlook For GlaxoSmithKline plc (NYSE:GSK)

Elias Hubbard
February 9, 2018

Jefferies has "Buy" rating and GBX 1900 target. The stock of GlaxoSmithKline plc (LON:GSK) has "Buy" rating given on Thursday, October 26 by Liberum Capital. BNP Paribas maintained the stock with "Neutral" rating in Wednesday, April 13 report. The rating was maintained by Credit Suisse on Friday, July 21 with "Neutral". The rating was maintained by Shore Capital with "Hold" on Tuesday, February 14.

TRADEMARK VIOLATION NOTICE: "GlaxoSmithKline (GSK) Rating Lowered to C at TheStreet" was originally reported by StockNewsTimes and is the property of of StockNewsTimes. Morgan Stanley has "Equal-Weight" rating and $27 target. Cowen set a $38.00 price target on GlaxoSmithKline and gave the company a "hold" rating in a research note on Monday, December 11th. On Thursday, October 20 the stock rating was initiated by Investec with "Buy". (NYSE:BCE) earned "Underperform" rating by Macquarie Research on Tuesday, October 27.

The stock increased 2.10% or $0.06 during the last trading session, reaching $2.92. About 2.45 million shares traded. Peabody Energy Corporation (NYSE:BTU) has 0.00% since February 9, 2017 and is. It has underperformed by 12.44% the S&P500.

Peabody Energy Corporation Peabody engages in coal mining business.

The company shows its Return on Assets (ROA) value of 4%. The firm operates through six operating divisions: Powder River Basin Mining, Midwestern U.S. It has a 10.87 P/E ratio. If you are accessing this article on another website, it was illegally stolen and republished in violation of US and worldwide copyright law.

In case of Revenue Estimates, 4 analysts have provided their consensus Average Revenue Estimates for GlaxoSmithKline plc as 10.55 Billion. They expect $0.64 EPS, down 1.54% or $0.01 from last year's $0.65 per share. GSK's profit will be $31.33 million for 505.55 P/E if the $0.64 EPS becomes a reality. The pharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.69 by $0.03.

Some buy side analysts are also providing their Analysis on GlaxoSmithKline plc, where 2 analysts have rated the stock as Strong buy, 1 analysts have given a Buy signal, 2 said it's a HOLD, and 0 analysts rated the stock as Sell. Therefore 44% are positive. Analysts reported that the Price Target for GlaxoSmithKline plc might touch $53.77 high while the Average Price Target and Low price Target is $42.15 and $28.39 respectively. GlaxoSmithKline presently has an average rating of "Hold" and an average target price of $38.57.

Huntington National Bank decreased its holdings in GlaxoSmithKline plc (NYSE:GSK) by 7.6% during the 4th quarter, Holdings Channel reports. The rating was maintained by Jefferies with "Buy" on Friday, July 29. The company was maintained on Thursday, February 8 by Kepler Cheuvreux. The stock has "Buy" rating by Beaufort Securities on Tuesday, October 25. ValuEngine downgraded GlaxoSmithKline from a "buy" rating to a "hold" rating in a research report on Sunday, December 31st. The firm has "Neutral" rating by JP Morgan given on Monday, July 24. The company had Year Ago Sales of 9.41 Billion. It operates through four divisions: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. It has a 17.25 P/E ratio. The firm offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. The firm owned 22,983 shares of the pharmaceutical company's stock after selling 1,899 shares during the quarter. Fmr Llc owns $706.2 million in GlaxoSmithKline plc, which represents roughly 0.79% of the company's market cap and approximately 8.38% of the institutional ownership.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER